Additionally, renal outcomes from randomized clinical trials (RCTs) have demonstrated other benefits of SGLT-2 inhibitors, such as delayed progression to end-stage kidney disease (ESKD), reduced glomerular hyperfiltration and proteinuria, and improved cardiovascular outcomes and all-cause mortality [1,2,4], even in patients with advanced chronic kidney disease (ACKD) with and without T2DM going down to an estimated glomerular filtration rate (eGFR) of 20 mL/min/per 1.73 m2 [3]. This evidence concerns the gene SLC5A2 and chronic kidney disease.